Systems Pharmacology of VEGF165b in Peripheral Artery Disease
Abstract
We built a whole‐body computational model to study the role of the poorly understood vascular endothelial growth factor (VEGF)165b splice isoform in peripheral artery disease (PAD). This model was built and validated using published and new experimental data from cells, mice, and humans, and explicitly accounts for known properties of VEGF165b: lack of extracellular matrix (ECM)‐binding and weak phosphorylation of vascular endothelial growth factor receptor‐2 (VEGFR2) in vitro. The resulting model captures all known information about VEGF165b distribution and signaling in human PAD, and provides novel, nonintuitive insight into VEGF165b mechanism of action in vivo. Although VEGF165a and VEGF165b compete for VEGFR2 in vitro, simulations show that these isoforms do not compete for VEGFR2 at much lower physiological concentrations. Instead, reduced VEGF165a may drive impaired VEGFR2 signaling. The model predicts that VEGF165b does compete for binding to VEGFR1, supporting a VEGFR1‐mediated response to anti‐VEGF165b. The model predicts a key role for VEGF165b in PAD, but in a different way than previously hypothesized.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 28, 2017
- Source ID
- 10.1002/psp4.12261
Entities
People
- Brian H. Annex
- Feilim Mac Gabhann
- Lindsay E Clegg
- Vijay C. Ganta
Organizations
- American Heart Association
- Johns Hopkins University
- University of Virginia